A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray

NCT07259538 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Rhinosinusitis (CRS)

Interventions

DRUG: 0.5% VVN432 Nasal Spray
DRUG: 1% VVN432 Nasal Spray
DRUG: Vehicle

Sponsor

VivaVision Biotech, Inc